Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsIntellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisSeptember 16, 2022Webinar: “Progress in Amyloidosis: 2022”July 14, 2022Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL AmyloidosisSeptember 8, 2026 Previous postWebMD EducationNext postAttralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis